Abstracts tagged "Outcome measures"

Abstract Number: 0727 • ACR Convergence 2020
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
Naveen R¹, Namita Mohindra¹, Neeraj Jain¹ and Amita Aggarwal², ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
Abstract Number: 1157 • ACR Convergence 2020
Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed for a Median of Fifteen Years
Sara Alehashemi¹, Megha Garg², Kim Johnson³, Kelly King⁴, Chris Zalewski⁴, Debbie Payne⁵, Adriana de Jesus⁶, Joseph Snow⁷, Wadih Zein⁵, M. Teresa Magone⁵, Rachel Bishop⁸, Carmen Brewer⁴, Jeff Kim⁴, Scott Paul⁹, John Butman¹⁰ and Raphaela Goldbach-Mansky¹¹, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ²NIH/NIAID, Rochester, NY, ³NIH, NIAID, Bethesda, ⁴NIH, NIDCD, Bethesda, MD, ⁵NIH/NEI, Bethesda, MD, ⁶Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁷NIH, NIMH, Bethesda, MD, ⁸NIH, NEI, Bethesda, MD, ⁹NIH, CC/RMD, Bethesda, MD, ¹⁰NIH, CC/DRD, Bethesa, MD, ¹¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Patients (pts) with NOMID have systemic inflammation and organ damage such as sensorineural hearing loss, hydrocephalus, optic nerve atrophy and growth plate defects. IL-1 blocking…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: 341 • 2019 ACR/ARP Annual Meeting
Development of a Multivariable Improvement Measure for Gout
Naomi Schlesinger¹, N. Lawrence Edwards ², Anthony Yeo ³ and Peter Lipsky ⁴, ¹Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Department of Medicine, University of Florida, Gainesville, FL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Gout is a multifactorial inflammatory disease in which patients experience a wide range of signs and symptoms, including flares, inflammatory arthritis, tophi and disability.…
Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Till Uhlig¹, Lars Fridtjof Karoliussen ², Espen A Haavardsholm ², Tore Kvien ¹ and Hilde Hammer ², ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Diakonhjemmet hospital, Oslo, Norway
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 1655 • 2019 ACR/ARP Annual Meeting
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Cynthia Magro ², Dana Orange ³, Yaxia Zhang ⁴, Phaedra Agius ⁵, Jackie Finik ⁶, Robert Spiera ¹ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³Rockefeller University, New York, ⁴Hospital for Special Surgery, New York, ⁵New York Genome Center, New York City, ⁶Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Didem Saygin¹, Chester Oddis ¹, Nicole Neiman ¹, Diane Koontz ¹, Siamak Moghadam-Kia ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…
Abstract Number: 1446 • 2018 ACR/ARHP Annual Meeting
The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model
Elizabeth M.A. Hensor^1,2, Alan Tennant³, Philip G. Conaghan^1,2, Hilde B Hammer⁴, Richard J. Wakefield^1,2 and Maria Antonietta D'Agostino^1,5, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, United Kingdom, ³Swiss Paraplegic Research, Nottwil, Switzerland, ⁴Rheumatology, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology, Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France
Background/Purpose: The recently introduced composite OMERACT-EULAR power Doppler (PD)/grey scale (GS) ultrasound (PDUS) scoring system for RA with a proposed 18 joint set was developed…
Abstract Number: 2906 • 2018 ACR/ARHP Annual Meeting
Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy
Daniel Kuo¹, Gurjit Kaeley², Ami Ben-Artzi³, Jenny Brook⁴, Astrid Floegel-Shetty⁴, David Elashoff⁴ and Veena K. Ranganath¹, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Rheumatology, Cedars Sinai Medical Center, Beverly Hills, CA, ⁴Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Musculoskeletal ultrasound is increasingly being used as a tool to assess inflammatory burden in rheumatoid arthritis (RA). Ultrasound-based outcome measures include power Doppler (PD)…
Abstract Number: 1455 • 2018 ACR/ARHP Annual Meeting
Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence
Jose M Lezcano¹, José Ivorra-Cortes², Alfredo Madrid³, Raquel Lopez-Mejías⁴, Javier Martin⁵, Benjamín Fernández-Gutiérrez⁶, Miguel Angel González-Gay⁷, Alejandro Balsa⁸, Isidoro Gonzalez-Alvaro⁹, Fernando Salazar¹⁰, Lydia A Alcazar¹¹ and Luis Rodriguez-Rodriguez¹¹, ¹Helix BioS CEO, Madrid, Spain, ²Rheumatology, University Hospital la Fe, Valencia, Spain, ³Rheumatology Department, and Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁵Instituto de Parasitología y Biomedicina López Neyra, Granada, Spain, ⁶Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ⁷School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁹Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ¹⁰International Centre for Numerical Methods in Engineering (CIMNE), Madrid, Spain, ¹¹Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased mortality and disability. Although different factors have been associated with prognosis, it is…
Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
Shanthini Kasturi¹, Jackie Szymonifka², Jessica R. Berman³, Kyriakos A. Kirou³, Alana B. Levine³, Lisa R Sammaritano⁴ and Lisa A. Mandl⁴, ¹Medicine/Rheumatology, Tufts Medical Center, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…
Abstract Number: 1512 • 2018 ACR/ARHP Annual Meeting
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Gurjit Kaeley², Jennifer Wang³, Ani Shahbazian³, Jenny Brook⁴, David Elashoff⁴ and Veena K. Ranganath⁵, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UF Health Jacksonville, Jacksonville, FL, ³University of California, Los Angeles, Los Angeles, CA, ⁴Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Musculoskeletal ultrasound (MSUS) can detect synovitis by Power doppler (PDUS) and can predict erosive progression on xrays in rheumatoid arthritis (RA) patients. We previously…
Abstract Number: 2924 • 2018 ACR/ARHP Annual Meeting
Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort
Sofia Ramiro¹, Désirée van der Heijde², Alexandre Sepriano³, Miranda van Lunteren⁴, Anna Molto⁵, Maria Antonietta D'Agostino⁶, Damien Loeuille⁷, Maxime Dougados⁸, M. Reijnierse⁹ and Pascal Claudepierre¹⁰, ¹Zuyderland Medical Center, Heerlen & Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, ⁷Rheumatology, University Hospital of Nancy, NANCY, France, ⁸Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁹Radiology, Leiden University Medical Center, Leiden, Netherlands, ¹⁰Hôpital Henri Mondor, Créteil, France
Background/Purpose: Spinal radiographic progression has been investigated in patients with r-axSpA, but not yet as thoroughly in early axSpA. We aimed to analyse the progression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].